Eli Lilly and Co. CEO Dave Ricks called the $8 billion buyout of Loxo Oncology Inc. "completely in line with what we've been talking about all along," although it's a deal "bigger than we've done before. In this case, you have four either clinical or recently approved medicines in one package, which is a bit unique for us." The bundle comes with a platform that may prove more broadly useful, he pointed out during a conference call with investors.